Janux Therapeutics (JANX) Operating Margin: 2020-2025
Historic Operating Margin for Janux Therapeutics (JANX) over the last 4 years, with Sep 2025 value amounting to -352.51%.
- Janux Therapeutics' Operating Margin rose 781195.00% to -352.51% in Q3 2025 from the same period last year, while for Sep 2025 it was -700.84%, marking a year-over-year decrease of 4207.00%. This contributed to the annual value of -933.58% for FY2024, which is 3071.00% down from last year.
- Janux Therapeutics' Operating Margin amounted to -352.51% in Q3 2025, which was up 95.68% from -8,164.46% recorded in Q3 2024.
- Over the past 5 years, Janux Therapeutics' Operating Margin peaked at -155.36% during Q2 2024, and registered a low of -8,164.46% during Q3 2024.
- Moreover, its 3-year median value for Operating Margin was -823.00% (2023), whereas its average is -1,814.97%.
- As far as peak fluctuations go, Janux Therapeutics' Operating Margin slumped by 753,622bps in 2024, and later skyrocketed by 781,195bps in 2025.
- Janux Therapeutics' Operating Margin (Quarterly) stood at -834.78% in 2021, then soared by 19,274bps to -642.04% in 2022, then plummeted by 1,367bps to -655.71% in 2023, then tumbled by 753,622bps to -8,164.46% in 2024, then soared by 781,195bps to -352.51% in 2025.
- Its Operating Margin was -352.51% in Q3 2025, compared to -8,164.46% in Q3 2024 and -155.36% in Q2 2024.